-
Press Release
2020/02/05
Abnova Speed Up Wuhan 2019-nCoV Rapid Test, Therapeutic Antibody and Vaccine Development
-
Press Release
2020/01/31
Abnova Uses Its Rapid DNAx™ Immune Technology for 2019-CoV Wuhan Coronavirus Antibody Production
-
Press Release
2020/01/09
Abnova Signup More Cancer Clinics and Hospitals and Expands its Circulating Tumor Cells and Precision Medicine Business in Japan
-
Press Release
2019/12/19
Abnova Upgrades its Antibody Technology and Manufacturing for Researchers, Biotech and Pharmaceutical Customers Worldwide
-
Press Release
2019/11/13
Abnova Integrates CARlike-IL12 Technology and Setup a IL-12 Patent Portfolio Strategy for Gene Modified T cell Therapy
-
Press Release
2019/10/29
Abnova’s mutaFISH™ Probes Energize the Fluorescent In Situ Hybridization Global Market and Propel New Precision Medicine Applications
-
Press Release
2019/09/23
Abnova Subsidiary Wellconn Genomics™ Clinical Laboratory Introduces Germline Genetic Testing Service for Prostate Cancer Hereditary Predisposing Genes
-
Press Release
2019/08/26
Abnova Completes GMP Manufacturing Agreements and Appoints Aldevron and Lentigen to Manufacture the Respective Transfer Plasmid and Lentiviral Vector for its Gene-Modified T Cell Therapy Clinical Trials
-
Press Release
2019/05/28
Abnova & National Cancer Center Hospital East Japan Collaborate to Setup Decentralized, Point-of-Care, IL-12 Gene Modified T Cell Manufacturing for Cancer Therapy
-
Press Release
2019/05/06
Abnova Introduces LiquidCell™ Negative Enrichment Circulating Tumor Cell Platform for the Clinical Pathology Market